Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce D Cheson

Showing results (11-20 of 339) with videos related to

Pageof 34
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Letter from the editorBruce D Cheson
Therapeutics and Clinical Risk Management|May 14, 2008
Oblimersen for the treatment of patients with chronic lymphocytic leukemiaBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|May 23, 2008
Most important accomplishmentsBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|February 19, 2013
Letter from the editorBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Letter from the editorBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Letter from the editorBruce D Cheson
Blood|May 31, 2014
CLL and NHL: the end of chemotherapy?Bruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemiaBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|December 7, 2006
Risky managementBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|July 8, 2014
American Society of Hematology (ASH) meetingBruce D Cheson
Pageof 34

Showing results (11-20 of 339) with videos related to

Sort By:
Pageof 34
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Letter from the editorBruce D Cheson
Therapeutics and Clinical Risk Management|May 14, 2008
Oblimersen for the treatment of patients with chronic lymphocytic leukemiaBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|May 23, 2008
Most important accomplishmentsBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|February 19, 2013
Letter from the editorBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Letter from the editorBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Letter from the editorBruce D Cheson
Blood|May 31, 2014
CLL and NHL: the end of chemotherapy?Bruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemiaBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|December 7, 2006
Risky managementBruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|July 8, 2014
American Society of Hematology (ASH) meetingBruce D Cheson
Pageof 34